Corpus overview


MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

There are no SARS-CoV-2 protein terms in the subcorpus


SARS-CoV-2 Proteins
    displaying 1 - 6 records in total 6
    records per page

    Initial experience in Mexico with convalescent plasma in COVID-19 MESHD patients with severe respiratory failure, a retrospective case series

    Authors: Michel F. Martinez-Resendez; Fernando Castilleja-Leal; Alejandro Torres-Quintanilla; Augusto Rojas-Martinez; Gerardo Garcia-Rivas; Rocio Ortiz-Lopez; Victor Trevino; Reynaldo Lara-Medrano; Hiram Villanueva-Lozano; Teresa Ramirez-Elizondo; Victor Sanchez-Nava; Francisco Moreno-Hoyos; Alfonso Martinez-Thomae; Martin Hernandez-Torre; Carlos Diaz-Olachea; Servando Cardona-Huerta; Sylvia de la Rosa-Pacheco; Carlos Diaz-Garza; Paola Reynoso-Lobo; Alma R. Marroquin-Escamilla; Jessica G. Herrera-Gamboa; Fatima M. Alvarado-Monroy; Claudia D. Aguayo-Millan; Francisco F. Villegas-Macedo; Jesus E. Flores-Osorio; Daniel Davila-Gonzalez; Maria E. Diaz-Sanchez; Guillermo Torre-Amione

    doi:10.1101/2020.07.14.20144469 Date: 2020-07-20 Source: medRxiv

    Introduction: Hospital mortality due to COVID-19 MESHD in Mexico is high (32%) and as of today, effective treatment options are limited. More effective treatments that shorten hospital stay and reduce mortality are needed. Initial reports for the use of convalescent plasma (CP) therapy for COVID-19 MESHD appear promising. We describe a case series of eight patients with impending respiratory failure MESHD, who underwent CP therapy. Methods: Six male and two female (ages 31 to 79) patients that were admitted to the intensive-care unit for severe COVID-19 MESHD were transfused with two doses of CP (250 mL per dose, anti-SARS-CoV-2 IgG titers > 1:100). Donors were six SARS-CoV-2 infected MESHD males who remained asymptomatic for > 7 days and were negative for two nasopharyngeal RT-PCR tests. Clinical characteristics, inflammatory and cellular injury markers, chest X-ray findings and viral loads were analyzed before and after CP administration. Viral load association to disease severity was further analyzed on a separate cohort of asymptomatic vs hospitalized patients with COVID-19 MESHD. Results: Eight patients with respiratory failure MESHD were successfully discharged with a median length of stay of 22.5 (IQR 18.25-29.00). After CP therapy, we observed a reduction of C-reactive protein HGNC ( CRP HGNC) (median, 22.80 mg/dL vs. 1.63 mg/dL), and of procalcitonin (median, 0.27 ng/mL vs. 0.13 ng/mL). High-Sensitivity Cardiac Troponin I (hs- cTnI HGNC), Brain Natriuretic Peptide ( BNP HGNC) and Lactate Dehydrogenase (LDH) were lower, and a mild reduction of pulmonary infiltrates by chest X-ray was observed. Lastly, a reduction of viral load was after CP therapy was found. (log, median [IQR], 1.2 [0.70-2.20] vs. 0.25 [0.00-1.78]). We observed no adverse effects. Conclusions: CP could potentially be an effective therapeutic option for patients with severe COVID-19 MESHD. Clinical benefit needs to be studied further through randomized controlled trials.

    Anaemia is Associated with Severe Illness in COVID-19 MESHD: A Retrospective Cohort Study

    Authors: Zheying Tao; Mingyu Liu; Jingyi Wu; Jing Xu; Wei Chen; Zhitao Yang; Xiaoman Xu; Ling Liu; Ruwu Chen; Jingyuan Xie; Huiming Wang; Jialin Liu

    doi:10.21203/ Date: 2020-06-30 Source: ResearchSquare

    Background and objective: Anaemia MESHD commonly aggravates the severity of respiratory diseases MESHD, whereas thus far, no study has elucidated the impact of anaemiaonCorona Virus Disease MESHD 2019( COVID-19 MESHD). The aim of this study was to evaluate the clinical characteristics of patients with anaemia MESHD, and to further explore the relationship between anaemiaand the severity of COVID-19 MESHD.METHODS:In this single-center, retrospective, observational study, a total of 222 patients were recruited, including 79 patients with anaemia MESHD and 143 patients without anaemia MESHD. Clinical characteristics, laboratory findings, disease progression and prognosis were collected and analyzed. Risk factors associated with the severe illness in COVID-19 MESHDwere established by univariable and multivariable logistic regression models.Result:In our cohort, compared to patients without anaemia MESHD, patients with anaemia MESHD were more likely to experience one or more comorbidities and severe COVID-19 MESHD illness, as well as higher mortality. More patients demonstrated elevated levels of C-reactive protein HGNC ( CRP HGNC), procalcitonin(PCT) and creatinine in anaemia MESHD group. Levels of erythrocyte sedimentation rate(ESR), D-dimer, myoglobin, T-pro brain natriuretic peptide(T-pro- BNP HGNC) and urea nitrogen(BUN)in patients with anaemia MESHD were significantly higher than those without. In addition,the proportion of patients with dyspnoea,elevated CRP MESHD CRP HGNC and PCT was positively associated with the severity of anaemia MESHD. The Odd Ratio (OR) of anaemia MESHD related to the severe condition of COVID-19 MESHD was 5.07 (95% CI:1.82-14.18, P=0.002) and 3.47 (95% CI:1.02-11.75, P=0.046) after adjustment for baseline date and laboratory indices, respectively.Conclusion: Anaemia MESHD is an independent risk factor associated with the severe illness of COVID-19 MESHD, and healthcare professionals should be more sensitive to the haemoglobin levels of COVID-19 MESHD patients on admission. To avoid rapid deterioration, more intensive care should be given to patients with anaemia MESHD.Trial registration: Ethics committee of Wuhan University People's Hospital (wdry2020-k064)

    Laboratory findings in coronavirus disease 2019 MESHD ( COVID-19 MESHD) patients: a comprehensive systematic review and meta-analysis

    Authors: Mohammad Karimian; Amirreza Jamshidbeigi; Gholamreza Badfar; Milad Azami

    doi:10.1101/2020.06.07.20124602 Date: 2020-06-08 Source: medRxiv

    Background: In early December 2019, the first patient with COVID-19 MESHD pneumonia MESHD was found in Wuhan, Hubei Province, China. Recent studies have suggested the role of primary laboratory tests in addition to clinical symptoms for suspected patients, which play a significant role in the diagnosis of COVID-19 MESHD. Therefore, the present study was conducted to evaluate laboratory findings in COVID-19 MESHD patients. Material and methods: The present meta-analysis was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. This protocol is registered with the code CRD42019145410 in PROSPERO International Database. Results: Finally, 52 studies involving 5490 patients with COVID-19 MESHD entered the meta-analysis process. The prevalence of leukopenia MESHD, lymphopenia MESHD, elevated c-reactive protein HGNC ( CRP HGNC), elevated erythrocyte sedimentation rate (ESR), elevated serum amyloid A, elevated ferritin was estimated to be 20.9% (95%CI: 17.9-24.3), 51.6% (95%CI: 44.0-59.1), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 63.6% (95%CI: 57.0-69.8), 62.5% (95%CI: 50.1-73.5), 74.7% (95%CI: 50.0-89.7), and 72.6% (95%CI: 58.1-83.5), respectively. The prevalence of elevated interleukin-6 HGNC was 59.9% (95%CI: 48.2-70.5), CD3 was 68.3% (95%CI: 50.1-82.2), reduced CD4 HGNC was 62.0% (95%CI: 51.1-71.6), reduced CD8 HGNC was 42.7% (95%CI: 32.2-53.9). The prevalence of elevated troponin-I was 20.6% (95%CI: 9.0-40.5), elevated creatine kinase-MB (CKMB) was 14.7% (95%CI: 7.1-28.0), elevated brain natriuretic peptide ( BNP HGNC) was 48.9% (95%CI: 30.4-67.7), elevated blood urea nitrogen was 13.1% (95%CI: 6.6-24.4),, elevated creatinine was 7.2% (95%CI: 4.4-11.8), elevated lactate dehydrogenase (LDH) was 53.1% (95%CI: 43.6-62.4), hyperglycemia MESHD was 41.1% (95% CI: 28.2-55.5), elevated total bilirubin was 48.9% (95%CI: 30.4-67.7), reduced albumin was 54.7% (95%CI: 38.1-70.2), reduced pre-albumin was 49.0% (95%CI: 26.6-71.8), and reduced PT was 53.1% (95% CI: 43.6-62.4), and D-dimer was 44.9% (95%CI: 31.0-59.6). Conclusion This study provides a comprehensive description of laboratory characteristics in patients with COVID-19 MESHD. The results show that lymphopenia MESHD, elevated CRP HGNC, elevated ESR, elevated ferritin, elevated serum amyloid A, elevated BNP HGNC, reduced albumin, reduced pre-albumin, reduced CD3, reduced CD4 HGNC, reduced CD8 HGNC, elevated D-dimer, reduced PT, elevated interleukin-2 HGNC, elevated interleukin-6 HGNC, elevated LDH and hyperglycemia MESHD are the common findings at the time of admission.

    Single-cell Transcriptome Analysis Indicates New Potential Regulation Mechanism of ACE2 HGNC and NPs signaling among heart failure patients infected with SARS-CoV-2

    Authors: Xiaojiang Xu; Dachun Xu; Hong Li; Mengqiu Ma; Yanhua Xu; Yang Su; Sang-Bing Ong; Xindong Hu; Min Cai; Maojun Zhao; Yingjie Chen

    doi:10.1101/2020.04.30.20081257 Date: 2020-05-05 Source: medRxiv

    Background: COVID-19 MESHD patients with comorbidities such as hypertension MESHD or heart failure MESHD ( HF MESHD) are associated with poor clinical outcomes. Angiotensin-converting enzyme 2 HGNC ( ACE2 HGNC), the critical enzyme for SARS-CoV-2 infection MESHD, is broadly expressed in many organs including heart. However, the cellular distribution of ACE2 HGNC in the human heart, particularly the failing heart is unknown. Methods: We analyzed single-cell RNA sequencing (scRNA-seq) data in both normal and failing hearts, and characterized the ACE2 HGNC gene expression profile in various cell subsets, especially in cardiomyocyte subsets, as well as its interaction with gene networks relating to various defense and immune responses at the single cell level. Results: The results demonstrated that ACE2 HGNC is present in cardiomyocytes (CMs), endothelial cells, fibroblasts and smooth muscle cells in the heart, while the number of ACE2 HGNC-postive ( ACE2 HGNC+) CMs and ACE2 HGNC gene expression in these CMs are significantly increased in the failing hearts. Interestingly, both brain natriuretic peptides ( BNP HGNC) and atrial natriuretic peptide (ANP) are significantly up-regulated in the ACE2 HGNC+ CMs. Further analysis shows that ANP, BNP HGNC and ACE2 HGNC may form a negative feedback loop with a group of genes associated with the development of heart failure MESHD. To our surprise, we found that genes related to virus entry, virus replication and suppression of interferon-gamma HGNC signaling are all up-regulated in CMs in failing hearts, and the increases were significantly higher in ACE2 HGNC+ CMs as compared with ACE2 HGNC negative ( ACE2 HGNC-) CMs, suggesting that these ACE2 HGNC+ CMs may be more vulnerable to virus infection MESHD. Since ACE2 HGNC expression is correlated with BNP HGNC expression, we further performed retrospective analysis of the plasma BNP HGNC levels and clinic outcome of 91 COVID-19 MESHD patients from a single-center. Patients with higher plasma BNP HGNC were associated with significantly higher mortality rate and expression levels of inflammatory and infective markers such as procalcitonin and C-reactive protein HGNC. Conclusion: In the failing heart, the upregulation of ACE2 HGNC and virus infection MESHD associated genes, as well as the increased expression of ANP and BNP HGNC could facilitate SARS-CoV-2 virus entry and replication in these vulnerable cardiomyocyte subsets. These findings may advance our understanding of the underlying molecular mechanisms of myocarditis MESHD associated with COVID-19 MESHD.

    Clinical features and outcomes of 2019 novel coronavirus-infected patients with high plasma BNP HGNC levels

    Authors: youbin liu; Dehui Liu; Huafeng Song; Chunlin chen; Mingfang lv; Xing pei; Zhongwei Hu; Zhihui Qin; Jinglong Li

    doi:10.1101/2020.03.31.20047142 Date: 2020-04-02 Source: medRxiv

    Aims To explore clinical features and outcome of 2019 novel coronavirus(2019-nCoV)-infected patients with high BNP HGNC levels Methods and results Data were collected from patients medical records, and we defined high BNP HGNC according to the plasma BNP HGNC was above > 100 pg/mL. In total,34 patients with corona virus disease MESHD 2019( COVID-19 MESHD)were included in the analysis. Ten patients had high plasma BNP HGNC level. The median age for these patients was 60.5 years (interquartile range, 40-80y), and 6/10 (60%) were men. Underlying comorbidities in some patients were coronary heart disease MESHD (n=2, 20%) ;hypertesion(n=3;30%);, heart failure MESHD (n=1,10%)and diabetes MESHD (n=2, 20%). Six (60%) patients had a history of Wuhan exposure. The most common symptoms at illness onset in patients were fever MESHD (n=7, 70%), cough (n=3, 30%), headache MESHD or fatigue MESHD(n=4,40%);. These patients had higher aspartate aminotransferase( AST HGNC), troponin I, C reactive protein HGNC and lower hemoglobin, and platelet count,compared with patients with normal BNP HGNC, respectively. Compared with patients with normal BNP HGNC, patients with high BNP HGNC were more likely to develop severe pneumonia MESHD, and receive tracheal cannula, invasive mechanical ventilation, continuous renal replacement therapy, extracorporeal membrane oxygenation, and be admitted to the intensive care unit. One patient with high BNP HGNC died during the study.

    Lactate dehydrogenase, a Risk Factor of Severe COVID-19 MESHD Patients

    Authors: Yi Han; Haidong Zhang; Sucheng Mu; Wei Wei; Chaoyuan Jin; Yuan Xue; Chaoyang Tong; Yunfei Zha; Zhenju Song; Guorong Gu

    doi:10.1101/2020.03.24.20040162 Date: 2020-03-27 Source: medRxiv

    BACKGROUND The World Health Organization (WHO) has recently declared coronavirus disease 2019 MESHD ( COVID-19 MESHD) a public health emergency of global concern. Updated analysis of cases might help identify the characteristic and risk factors of the illness severity. METHODS We extracted data regarding 47 patients with confirmed COVID-19 MESHD from Renmin Hospital of Wuhan University between February 1 and February 18, 2020. The degree of severity of COVID-19 MESHD patients (severe vs. non-severe) was defined at the time of admission according to American Thoracic Society (ATS) guidelines for community-acquired pneumonia MESHD (CAP). RESULTS The median age was 64.91 years, 26 cases (55.31%) were male of which, and 70.83% were severe cases. Severe patients had higher APACHE II (9.92 vs 4.74) and SOFA (3.0 vs 1.0) scores on admission, as well as the higher PSI (86.13 vs 61.39), Curb-65 (1.14 vs 0.48) and CT semiquantitative scores (5.0 vs 2.0) when compared with non-severe patients. Among all univariable parameters, APACHE II, SOFA, lymphocytes, CRP HGNC, LDH, AST HGNC, cTnI HGNC, BNP HGNC, et al were significantly independent risk factors of COVID-19 MESHD severity. Among which, LDH was most positively related both with APACHE II (R = 0.682) and SOFA (R = 0.790) scores, as well as PSI (R = 0.465) and CT (R = 0.837) scores. To assess the diagnostic value of these selected parameters, LDH (0.9727) had maximum sensitivity (100.00%) and specificity (86.67%), with the cutoff value of 283. As a protective factor, lymphocyte counts less than 1.045 x 109 /L showed a good accuracy for identification of severe patients with AUC = 0.9845 (95%CI 0.959-1.01), the maximum specificity (91.30%) and sensitivity (95.24%). In addition, LDH was positively correlated with CRP HGNC, AST HGNC, BNP HGNC and cTnI HGNC, while negatively correlated with lymphocyte cells and its subsets, including CD3+, CD4+ and CD8+ T cells (P < 0.01). CONCLUSIONS This study showed that LDH coule be identified as a powerful predictive factor for early recognition of lung injury MESHD and severe COVID-19 MESHD cases. And importantly, lymphocyte counts, especially CD3+, CD4+, and CD8+ T cells in the peripheral blood of COVID-19 MESHD patients, which was relevant with serum LDH, were also dynamically correlated with the severity of the disease. FUNDING Key Project of Shanghai Municipal Health Bureau (2016ZB0202)

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.